Article info

Download PDFPDF

Original research
Immunogenicity and safety of a three-dose SARS-CoV-2 vaccination strategy in patients with immune-mediated inflammatory diseases on immunosuppressive therapy

Authors

  1. Correspondence to Dr Silje Watterdal Syversen; s.w.syversen{at}gmail.com
View Full Text

Citation

Syversen SW, Jyssum I, Tveter AT, et al
Immunogenicity and safety of a three-dose SARS-CoV-2 vaccination strategy in patients with immune-mediated inflammatory diseases on immunosuppressive therapy

Publication history

  • Received April 19, 2022
  • Accepted September 28, 2022
  • First published November 3, 2022.
Online issue publication 
November 03, 2022
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.